246 related articles for article (PubMed ID: 36137881)
1. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
[TBL] [Abstract][Full Text] [Related]
2. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
3. The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma.
Aslan V; Karabörk Kılıç AC; Özet A; Üner A; Günel N; Yazıcı O; Savaş G; Bayrak A; Eraslan E; Öksüzoğlu B; Kılıç HK; Özdemir N
BMC Cancer; 2023 Oct; 23(1):1045. PubMed ID: 37904131
[TBL] [Abstract][Full Text] [Related]
4. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the cachexia index using a bioelectrical impedance analysis in elderly patients with non-Hodgkin's lymphoma: A single-center prospective study.
Okubo S; Shinmura K; Kadota S; Nakayasu M; Kurosawa S; Nakayama H; Sakurai A; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2024 Mar; 103(3):823-831. PubMed ID: 38010408
[TBL] [Abstract][Full Text] [Related]
6. Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B-cell lymphoma.
Go SI; Park MJ; Park S; Kang MH; Kim HG; Kang JH; Kim JH; Lee GW
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):2211-2219. PubMed ID: 34676685
[TBL] [Abstract][Full Text] [Related]
7. Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma.
Herrmann T; Mione C; Montoriol PF; Molnar I; Ginzac A; Durando X; Mahammedi H
Oncology; 2022; 100(2):114-123. PubMed ID: 34999587
[TBL] [Abstract][Full Text] [Related]
8. Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patients.
Jafri SH; Previgliano C; Khandelwal K; Shi R
Clin Med Insights Oncol; 2015; 9():87-93. PubMed ID: 26604850
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of the cachexia index in patients with small cell lung cancer.
Go SI; Park MJ; Lee GW
BMC Cancer; 2021 May; 21(1):563. PubMed ID: 34001060
[TBL] [Abstract][Full Text] [Related]
10. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
[No Abstract] [Full Text] [Related]
11. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O; Master VA; Bilen MA
Oncologist; 2020 Mar; 25(3):e484-e491. PubMed ID: 32162798
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of cachexia index in patients with hepatocellular carcinoma after hepatic resection.
Akaoka M; Haruki K; Taniai T; Yanagaki M; Igarashi Y; Furukawa K; Onda S; Tsunematsu M; Shirai Y; Okui N; Gocho T; Ikegami T
Surg Oncol; 2022 Dec; 45():101881. PubMed ID: 36371905
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy.
Goh MJ; Kang W; Jeong WK; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Sci Rep; 2022 May; 12(1):7647. PubMed ID: 35538112
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract][Full Text] [Related]
15. Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Khan AI; Psutka SP; Patil DH; Hong G; Williams MA; Bilen MA; Sekhar A; Kissick HT; Narayan VM; Joshi SS; Ogan K; Master VA
Cancer; 2022 Jun; 128(11):2073-2084. PubMed ID: 35285950
[TBL] [Abstract][Full Text] [Related]
16. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.
Ueki H; Hara T; Okamura Y; Bando Y; Terakawa T; Furukawa J; Harada K; Nakano Y; Fujisawa M
Investig Clin Urol; 2022 Jul; 63(4):415-424. PubMed ID: 35796138
[TBL] [Abstract][Full Text] [Related]
17. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment.
Ishihara H; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
Target Oncol; 2016 Oct; 11(5):605-617. PubMed ID: 27023922
[TBL] [Abstract][Full Text] [Related]
19. Association between Immune Checkpoint Inhibitor Treatment Outcomes and Body Composition Factors in Metastatic Renal Cell Carcinoma Patients.
Takei K; Kijima T; Okubo N; Kurashina R; Kokubun H; Uematsu T; Betsunoh H; Yashi M; Kamai T
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067295
[TBL] [Abstract][Full Text] [Related]
20. Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents.
Teishima J; Goto K; Sekino Y; Mita K; Hayashi T; Hasegawa Y; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Kobayashi K; Asano K; Hinata N
Int Urol Nephrol; 2022 Jun; 54(6):1225-1232. PubMed ID: 35314918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
